Eight-plasmid system for rapid generation of influenza virus vaccines.
about
Evolution of H5N1 avian influenza viruses in AsiaVaccines and antiviral drugs in pandemic preparednessSerum amyloid P is a sialylated glycoprotein inhibitor of influenza A virusesGeneration of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse geneticsThe intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and miceA contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virusActivation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe pathophysiology and diseaseA mouse model for the study of contact-dependent transmission of influenza A virus and the factors that govern transmissibilityProtective efficacy of a high-growth reassortant swine H3N2 inactivated vaccine constructed by reverse genetic manipulationEvaluation of the efficacy and cross-protectivity of recent human and swine vaccines against the pandemic (H1N1) 2009 virus infectionAvian influenza viruses inhibit the major cellular signalling integrator c-Abl.Mechanism of influenza A virus NS1 protein interaction with the p85beta, but not the p85alpha, subunit of phosphatidylinositol 3-kinase (PI3K) and up-regulation of PI3K activity.SH3 binding motif 1 in influenza A virus NS1 protein is essential for PI3K/Akt signaling pathway activation.Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs.Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from cold-adapted A/Ann Arbor/6/60.Pandemics, avian influenza A (H5N1), and a strategy for pharmacists.PC61 (anti-CD25) treatment inhibits influenza A virus-expanded regulatory T cells and severe lung pathology during a subsequent heterologous lymphocytic choriomeningitis virus infection.The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus.Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.All-in-one bacmids: an efficient reverse genetics strategy for influenza A virus vaccines.Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.New insights into the nonconserved noncoding region of the subtype-determinant hemagglutinin and neuraminidase segments of influenza A viruses.New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.The matrix gene segment destabilizes the acid and thermal stability of the hemagglutinin of pandemic live attenuated influenza virus vaccinesExpression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumoniaVirulence determinants in the PB2 gene of a mouse-adapted H9N2 virus.Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.Evidence of expanded host range and mammalian-associated genetic changes in a duck H9N2 influenza virus following adaptation in quail and chickens.Pathogenicity and vaccine efficacy of different clades of Asian H5N1 avian influenza A viruses in domestic ducks.Toward a broadly protective influenza vaccineAltered viral replication and cell responses by inserting microRNA recognition element into PB1 in pandemic influenza A virus (H1N1) 2009.Experimental infection of pigs with the human 1918 pandemic influenza virusConstruction and Immunogenicity Evaluation of Recombinant Influenza A Viruses Containing Chimeric Hemagglutinin Genes Derived from Genetically Divergent Influenza A H1N1 Subtype Viruses.Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells.A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models.Reference viruses for seasonal and pandemic influenza vaccine preparation.Zanamivir-resistant influenza viruses with a novel neuraminidase mutationThe effects of influenza A virus PB1-F2 protein on polymerase activity are strain specific and do not impact pathogenesisProtective memory responses are modulated by priming events prior to challenge.
P2860
Q21559381-FC3B47CA-4D93-4D85-AABB-9503D25EAFC9Q22305646-E0A64697-37F8-4CCD-B263-C030A520CBBAQ24337745-BACC698A-2230-4437-8569-AD46A7C26899Q24607062-59940371-2607-461F-9B28-52F58AAC37D4Q24650268-AE0AFC21-C8CB-4ED7-BED7-A9A47D3A7894Q27301043-5BF80D3E-7F1F-456E-8E27-91DAFEC566DCQ27316330-EE280CCE-EBBF-48E2-A47A-A24A37425DF1Q27334659-BAC02D0D-C47A-4880-9BB4-4555570E34E9Q28390990-99F56F27-A219-46FF-9739-CA389570C15CQ28394975-1A858D0C-0322-41D1-BFFF-5C7398BBFA2CQ28749544-52265A1E-3DA7-4298-B1B5-E1E16503D689Q30009343-65F0DA90-380E-4DA1-A8B9-A43B3D163AB5Q30157667-F1D4A656-BF13-4A66-B5C4-A0310A5BBAB2Q30157758-D9D09F3C-724E-4FE2-95E3-E2B1D5591F41Q30203790-37028D44-8702-443D-8E53-B2D7865BFB9BQ30336518-6EE9FB88-D346-4F80-ABD3-F749B0A4CF30Q30353151-C9BA8A9E-53B3-4188-BD8F-D216ACD9EBE9Q30353758-CE0B0076-7E64-476B-90F6-2AE5D1FE07FAQ30354732-CA46704A-15EA-444A-8113-CEDC482F9D8AQ30360869-D8C0F2C9-BCF8-42A0-87BB-11C849B357ECQ30363730-F89F0667-9B2A-423F-B59E-3727E19BE8CBQ30364619-CD664029-3F4E-4E5D-87F1-1F68C9AFC6A7Q30365054-420F89F1-A324-41C2-BA22-CF1D5C4419C5Q30365380-869E0F62-C4E6-47BF-A4F4-9C09B9F28113Q30365696-8968FB9E-C1B3-4462-8E63-C192DE9927D5Q30365855-4FB9CC10-6F08-42FE-8317-C5701113B352Q30368036-A699A56B-22CB-47E7-8D26-C81EAA8DE2CBQ30369828-075ECE0A-A8D5-417A-8EB0-AB6FFCBCE979Q30371926-2453FD22-0225-4DEA-A123-C3408AF17056Q30372021-7247D0F3-8E4E-458D-9607-93D5026022B9Q30372130-7CB01872-9760-487A-8F83-9DB93C90A969Q30372845-ABF90C8D-DC81-486A-ADA9-DA01C5BA0B0BQ30374993-BB2A1AA6-CB43-402B-9593-497513DAF217Q30375514-8265D1D2-D241-4A96-8AA3-87C23351992DQ30377222-73D79FCD-A0AD-4E43-A6DE-7608EF298E1FQ30377246-BBFC94A8-7195-47B1-8E15-584BC66272ADQ30377340-47CB542F-BF48-4E72-8A01-B73A9C09C44BQ30379353-A80DB212-CEBB-426B-827D-67D9BC09C5DFQ30381642-E1473A34-1193-4BE1-9E50-9ED2161AB0D4Q30382279-6FEF92C4-9140-428C-A1EC-DA7F32A10C99
P2860
Eight-plasmid system for rapid generation of influenza virus vaccines.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Eight-plasmid system for rapid generation of influenza virus vaccines.
@en
type
label
Eight-plasmid system for rapid generation of influenza virus vaccines.
@en
prefLabel
Eight-plasmid system for rapid generation of influenza virus vaccines.
@en
P50
P1433
P1476
Eight-plasmid system for rapid generation of influenza virus vaccines.
@en
P2093
Erich Hoffmann
Scott Krauss
P304
P356
10.1016/S0264-410X(02)00268-2
P407
P577
2002-08-01T00:00:00Z